Nomura Asset Management Co. Ltd. Buys 21,403 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Nomura Asset Management Co. Ltd. grew its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 7.3% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 314,069 shares of the medical research company's stock after purchasing an additional 21,403 shares during the quarter. Nomura Asset Management Co. Ltd. owned approximately 0.08% of Thermo Fisher Scientific worth $163,388,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of TMO. Legacy Investment Solutions LLC bought a new stake in shares of Thermo Fisher Scientific in the 3rd quarter worth approximately $26,000. Barrett & Company Inc. bought a new stake in shares of Thermo Fisher Scientific in the 4th quarter valued at about $28,000. FPC Investment Advisory Inc. purchased a new stake in Thermo Fisher Scientific during the 4th quarter valued at about $28,000. Pillar Financial Advisors LLC purchased a new position in Thermo Fisher Scientific in the 4th quarter worth approximately $29,000. Finally, Missouri Trust & Investment Co purchased a new stake in shares of Thermo Fisher Scientific during the fourth quarter valued at approximately $29,000. 89.23% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, SVP Michael A. Boxer sold 3,775 shares of Thermo Fisher Scientific stock in a transaction on Monday, March 10th. The stock was sold at an average price of $532.52, for a total value of $2,010,263.00. Following the completion of the sale, the senior vice president now owns 10,816 shares of the company's stock, valued at $5,759,736.32. The trade was a 25.87 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Stephen Williamson sold 9,825 shares of the firm's stock in a transaction dated Tuesday, February 4th. The stock was sold at an average price of $585.59, for a total value of $5,753,421.75. Following the completion of the transaction, the chief financial officer now directly owns 27,296 shares in the company, valued at $15,984,264.64. The trade was a 26.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 23,900 shares of company stock valued at $13,106,062. Company insiders own 0.34% of the company's stock.

Remove Ads

Thermo Fisher Scientific Stock Down 1.5 %

Shares of NYSE TMO traded down $7.37 during trading on Tuesday, reaching $490.23. The company had a trading volume of 707,954 shares, compared to its average volume of 1,915,481. The business's 50-day moving average is $540.37 and its 200 day moving average is $551.02. The company has a quick ratio of 1.29, a current ratio of 1.66 and a debt-to-equity ratio of 0.59. The stock has a market cap of $184.94 billion, a PE ratio of 29.66, a P/E/G ratio of 2.99 and a beta of 0.79. Thermo Fisher Scientific Inc. has a 12-month low of $484.27 and a 12-month high of $627.88.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its earnings results on Thursday, January 30th. The medical research company reported $6.10 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.94 by $0.16. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. As a group, equities analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 15th. Investors of record on Friday, March 14th will be given a dividend of $0.43 per share. This is an increase from Thermo Fisher Scientific's previous quarterly dividend of $0.39. The ex-dividend date of this dividend is Friday, March 14th. This represents a $1.72 dividend on an annualized basis and a yield of 0.35%. Thermo Fisher Scientific's dividend payout ratio is 10.41%.

Analysts Set New Price Targets

Several equities research analysts have weighed in on the stock. Citigroup dropped their price target on shares of Thermo Fisher Scientific from $650.00 to $570.00 and set a "neutral" rating for the company in a research report on Tuesday, March 4th. Bank of America reduced their price target on Thermo Fisher Scientific from $675.00 to $660.00 and set a "buy" rating on the stock in a report on Friday, December 13th. Raymond James reiterated an "outperform" rating and issued a $667.00 price objective (up from $650.00) on shares of Thermo Fisher Scientific in a research report on Monday, February 3rd. Scotiabank raised their price target on Thermo Fisher Scientific from $605.00 to $650.00 and gave the stock a "sector perform" rating in a research note on Monday, February 3rd. Finally, UBS Group boosted their price objective on shares of Thermo Fisher Scientific from $700.00 to $715.00 and gave the company a "buy" rating in a research report on Friday, January 31st. Four analysts have rated the stock with a hold rating and nineteen have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, Thermo Fisher Scientific presently has a consensus rating of "Moderate Buy" and a consensus price target of $653.23.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.